ASH Clinical News provides daily news and updates from the hematology/oncology community. Here are your weekly highlights: |
|
FDA Approves Betrixaban for VTE Prophylaxis Based on the APEX trial, the U.S. Food and Drug Administration has approved the new oral anticoagulant betrixaban for prophylactic treatment of adults at risk for venous thromboembolism. |
|
Patients’ Access to Treatment Act Introduced in House of Representatives ASH President Kenneth C. Anderson, MD, expressed support for a bill that would decrease the cost of co-payments for expensive specialty-tier medications. |
|
FDA Approves Rituximab Hyaluronidase Combination for FL, DLBCL, and CLL The U.S. Food and Drug Administration has approved a new subcutaneous injection formulation of rituximab and hyaluronidase for several hematologic malignancies. |
| Visit our website for all of our Online Exclusive news. |
This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England. One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
10 July 2017 (Monday) - ASH Update
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment